Centura Pharmaceuticals

Executive Summary

Centura Pharmaceuticals is a US-based private generic drug company specializing in over-the-counter (OTC) topical anesthetic creams. Founded in 2015 and headquartered in Miami, Florida, the company markets its flagship 'BLT' product—a combination of Benzocaine, Lidocaine, and Tetracaine—for temporary relief of pain and itch. Operating as an FDA-registered OTC drug manufacturer, Centura sells directly to consumers through its e-commerce platform, bypassing traditional retail channels. The company's focus on a niche topical anesthetic market positions it within the broader $10B+ OTC pain relief industry, though it faces competition from established brands and generic alternatives. As a small private entity with no disclosed funding or valuation, Centura's growth prospects hinge on expanding its product line, securing retail partnerships, and navigating FDA regulatory requirements. The company's direct-to-consumer model offers margin advantages but limits market reach. Near-term catalysts include potential FDA approvals for new formulations (e.g., higher strength or different combinations), strategic collaborations with pharmacy chains or online retailers, and geographic expansion beyond the US. While the company's scale remains modest, its innovative BLT formulation and e-commerce agility could drive gradual market share gains in the OTC topical segment.

Upcoming Catalysts (preview)

• Q3 2026FDA approval for new BLT formulation or additional topical product40% success
• Q4 2026Retail partnership with national pharmacy chain (e.g., CVS, Walgreens) for distribution30% success
• TBDExpansion into Canadian or European OTC market via e-commerce or licensing deal25% success